Featured Research

from universities, journals, and other organizations

Researchers Synthesize Compounds For New Class Of Antibiotics

Date:
May 13, 1998
Source:
Boston University
Summary:
Researchers at Boston University and Scriptgen Pharmaceuticals, Inc., have successfully synthesized two compounds that open the door to the development of an entirely new class of antibiotics for use against today's increasingly drug-resistant bacteria as well as emerging forms of bacteria.

(Boston, Mass.) -- Researchers at Boston University and Scriptgen Pharmaceuticals, Inc., have successfully synthesized two compounds that open the door to the development of an entirely new class of antibiotics for use against today's increasingly drug-resistant bacteria as well as emerging forms of bacteria.

In a recent issue of the Journal of Organic Chemistry, the research team reported that they have chemically synthesized myxopyronin A and B, two natural compounds known to block replication of drug-resistant strains of bacteria. Before this breakthrough, the compounds could only be isolated from their bacterial source, a process that yielded quantities too small to be usable.

From a therapeutic standpoint, the compounds look particularly promising because of their selectivity. Harmful bacteria contain DNA-dependent polymerase enzymes, as do humans. Myxopyronin A and B attack the bacterial enzymes while leaving the human host alone.

In recent years, the incidence of infectious diseases has soared, along with deaths resulting from them. At the same time, the need for new antibiotics has risen steadily as bacteria have developed a resistance to existing drugs. The worldwide market for anti-infective drugs is now estimated to be $34 billion, and it is still growing.

"This is an exciting opportunity for the development of a new type of antibiotic," says James Panek, a professor of chemistry who led Boston University's participation in the project. "The chemical synthesis provides us with the means for generating the materials that can lead to new pharmaceuticals."

Scriptgen, a Waltham, MA, company that develops drugs to control the expression of genes, is now developing the processes for converting the raw materials of myxopyronin A and B into viable antibiotics.

"This is a significant breakthrough from a chemistry point of view, but it's the first step in the process, " said Michael G. Palfreyman, Vice President of Research and Development at Scriptgen. "Now we need to take myxopyronin and make it more drug-like. The synthesis was designed to allow us to make many analogs--many different candidates--so that doctors can choose the best one for the desired activity."


Story Source:

The above story is based on materials provided by Boston University. Note: Materials may be edited for content and length.


Cite This Page:

Boston University. "Researchers Synthesize Compounds For New Class Of Antibiotics." ScienceDaily. ScienceDaily, 13 May 1998. <www.sciencedaily.com/releases/1998/05/980513080643.htm>.
Boston University. (1998, May 13). Researchers Synthesize Compounds For New Class Of Antibiotics. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1998/05/980513080643.htm
Boston University. "Researchers Synthesize Compounds For New Class Of Antibiotics." ScienceDaily. www.sciencedaily.com/releases/1998/05/980513080643.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins